Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia.
Nutr Metab Cardiovasc Dis
; 32(1): 17-20, 2022 01.
Article
em En
| MEDLINE
| ID: mdl-34802854
ABSTRACT
Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&A format. AIM:
The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-related practical clinical issues. DATASYNTHESIS:
The data includes main phase III studies, subanalysis and meta-analysis on BA.CONCLUSIONS:
The panel permitted collection of its opinions in a ten Q&A format.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ácidos Dicarboxílicos
/
Ácidos Graxos
/
Hiperlipidemias
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article